These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 8373062

  • 1. Prevention of cerebral edema by the vasopressin antagonist d(CH2)5D-Ile2Ile4Ala9AVP in rats with experimental subarachnoid hemorrhage.
    László FA, Varga C, Baláspiri L.
    Ann N Y Acad Sci; 1993 Jul 22; 689():627-9. PubMed ID: 8373062
    [No Abstract] [Full Text] [Related]

  • 2. Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate.
    László FA, Csáti S, Baláspiri L.
    Acta Endocrinol (Copenh); 1984 May 22; 106(1):56-60. PubMed ID: 6730855
    [Abstract] [Full Text] [Related]

  • 3. Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.
    László FA, Baláspiri L.
    Acta Med Hung; 1986 May 22; 43(3):333-9. PubMed ID: 3588172
    [Abstract] [Full Text] [Related]

  • 4. Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats.
    Rosenberg GA, Scremin O, Estrada E, Kyner WT.
    Stroke; 1992 Dec 22; 23(12):1767-73; discussion 1773-4. PubMed ID: 1448828
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A specific antagonist of vasopressin produced plasma hyperosmolality and reduced ischemic-induced cerebral edema in rats.
    Tang AH, Ho PM.
    Life Sci; 1988 Dec 22; 43(5):399-403. PubMed ID: 3398706
    [Abstract] [Full Text] [Related]

  • 7. Effect of vasopressin antagonist d(CH2)5Tyr(Et)VAVP on plasma arginine vasopressin level after osmotic stimulus.
    László FA, Laczi F, Janáky T, Baláspiri L.
    Endocr Regul; 1991 Sep 22; 25(3):181-3. PubMed ID: 1764609
    [Abstract] [Full Text] [Related]

  • 8. Involvement of vasopressin in brain edema formation: further evidence obtained from the Brattleboro diabetes insipidus rat with experimental subarachnoid hemorrhage.
    Dóczi T, László FA, Szerdahelyi P, Joó F.
    Neurosurgery; 1984 Apr 22; 14(4):436-41. PubMed ID: 6728146
    [Abstract] [Full Text] [Related]

  • 9. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.
    László FA, Varga C, Nakamura S.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):115-22. PubMed ID: 9932713
    [Abstract] [Full Text] [Related]

  • 10. Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin.
    László FA, Varga C, Dóczi T.
    Acta Neurochir (Wien); 1995 Jan 08; 133(3-4):122-33. PubMed ID: 8748754
    [Abstract] [Full Text] [Related]

  • 11. Effect of the vasopressin antagonist d/CH2/5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin.
    László FA, Csáti S, Baláspiri L.
    Acta Endocrinol (Copenh); 1984 May 08; 106(1):52-5. PubMed ID: 6730854
    [Abstract] [Full Text] [Related]

  • 12. Discovery and therapeutic utility of vasopressin antagonists in rats.
    Kinter LB, Dytko G, Ashton D, McDonald J, Huffman W, Stassen F.
    J Cardiovasc Pharmacol; 1986 May 08; 8 Suppl 7():S36-43. PubMed ID: 2434770
    [Abstract] [Full Text] [Related]

  • 13. Development of the Schwartz-Bartter syndrome after the administration of chlorpropamide and 1-deamino-8-D-arginine vasopressin.
    Valkusz Z, Laczi F, László FA.
    Endokrinologie; 1982 Jul 08; 79(3):345-8. PubMed ID: 7128548
    [No Abstract] [Full Text] [Related]

  • 14. Effects of drugs on water metabolism.
    Lee MR.
    Br J Clin Pharmacol; 1981 Sep 08; 12(3):289-93. PubMed ID: 7295458
    [No Abstract] [Full Text] [Related]

  • 15. Alleviation of brain edema by L-arginine following experimental subarachnoid hemorrhage in a rat model.
    Yang MF, Sun BL, Xia ZL, Zhu LZ, Qiu PM, Zhang SM.
    Clin Hemorheol Microcirc; 2003 Sep 08; 29(3-4):437-43. PubMed ID: 14724372
    [Abstract] [Full Text] [Related]

  • 16. A V1 vasopressin receptor antagonist has nonspecific neurodepressant actions in the spinal cord.
    Porter JP, Brody MJ.
    Neuroendocrinology; 1986 Sep 08; 43(1):75-8. PubMed ID: 3012394
    [Abstract] [Full Text] [Related]

  • 17. Effect of the aquaretic vasopressin antagonists d(CH2)5[D-Tyr(Et)2-Val4]AVP and d(CH2)5[D-Phe2-Phe4]AVP on urine production in healthy dogs.
    van Oosterhout IC, Rijnberk A, Mol JA.
    Horm Metab Res; 1992 May 08; 24(5):244-5. PubMed ID: 1398466
    [No Abstract] [Full Text] [Related]

  • 18. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus).
    Kinter LB, Churchill S, Stassen FL, Moore M, Huffman W.
    J Pharmacol Exp Ther; 1987 Jun 08; 241(3):797-803. PubMed ID: 3598903
    [Abstract] [Full Text] [Related]

  • 19. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Jun 08; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 20. Prostaglandin E--vasopressin interrelation in the syndrome of inappropriate secretion of antidiuretic hormone.
    Hsieh BS.
    Taiwan Yi Xue Hui Za Zhi; 1983 Apr 08; 82(4):481-9. PubMed ID: 6579203
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.